Get the Stockscreener App
0.00
100.00%
-14.00
Ventyx Biosciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$14.00
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
0.00
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$14.00
52-Week Range:
$0.00
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(760) 407-6511
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
0.00 | 1.00B | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Ventyx Biosciences (VTYX) exec records option dispositions in $14 Lilly buyout - Stock Titan
Ventyx Biosciences (VTYX) cashed out at $14 per share in Eli Lilly merger - Stock Titan
COO’s Ventyx (VTYX) options cashed out as Eli Lilly merger closes - Stock Titan
Lilly–Ventyx (VTYX) merger cancels director stock options at $14 - Stock Titan
Ventyx Biosciences (VTYX) director’s options cancelled in Eli Lilly cash merger - Stock Titan
Ventyx (VTYX) director’s options and shares cashed out at $14 in Eli Lilly merger - Stock Titan
Eli Lilly deal converts Ventyx (VTYX) CMO’s shares and options to cash - Stock Titan
Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com
Ventyx Biosciences (VTYX) deregisters registered resale shares after merger - Stock Titan
Ventyx Biosciences (NASDAQ: VTYX) deregisters shares after Eli Lilly merger - Stock Titan
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com India
Ventyx Biosciences (VTYX) notifies Nasdaq of common stock delisting - Stock Titan
Ventyx Biosciences Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Ventyx Biosciences (NASDAQ: VTYX) shareholders get $14 cash in Eli Lilly buyout - Stock Titan
VTYX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ventyx Biosciences Shareholders Approve Merger With Eli Lilly - TipRanks
Ventyx Biosciences shareholders approve merger with Eli Lilly - Investing.com
Ventyx Biosciences (VTYX) investors approve Eli Lilly merger and executive pay - Stock Titan
Insider Sell: Is Skyward Specialty Insurance Group Inc attractive at current valuationWeekly Trend Recap & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
VTYX Should I Buy - Intellectia AI
Ventyx Biosciences Inc. (VTYX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Best Pharmaceutical Stocks To Follow NowFebruary 27th - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
GLAZER CAPITAL, LLC Acquires Significant Stake in Ventyx Biosciences Inc - GuruFocus
Ventyx Faces Eli Lilly Acquisition, Delisting and Litigation - TipRanks
Ventyx Biosciences agrees to $14.00 cash per share merger with Eli Lilly; HSR waiting period cleared - TradingView
242,229 Shares in Ventyx Biosciences, Inc. $VTYX Acquired by GSA Capital Partners LLP - MarketBeat
Monaco Asset Management SAM Sells 536,288 Shares of Ventyx Biosciences, Inc. $VTYX - MarketBeat
Does Ventyx Biosciences Inc. meet Warren Buffett’s criteria2025 Top Gainers & Stock Portfolio Risk Control - mfd.ru
Ventyx Biosciences, Inc. $VTYX Shares Sold by Cibc World Market Inc. - MarketBeat
Ventyx Biosciences (VTYX) to Release Earnings on Thursday - MarketBeat
Growth Value: Is Ventyx Biosciences Inc currently under institutional pressureWeekly Stock Report & Smart Money Movement Tracker - baoquankhu1.vn
Eli Lilly acquires Ventyx Biosciences in $1.2bn deal - Financier Worldwide
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
Can Ventyx Biosciences Inc. stock hit record highs againQuarterly Portfolio Summary & Free Community Supported Trade Ideas - mfd.ru
Eli Lilly, Ventyx Biosciences receive early termination from US FTC - MLex
Halper Sadeh LLC is Investigating Whether VAL, STKL, VTYX are Obtaining Fair Deals for their Shareholders - GlobeNewswire
VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investi - The National Law Review
Panic Selling: Does Ventyx Biosciences Inc have a sustainable dividendForecast Cut & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc.VTYX - Business Wire
Halper Sadeh LLC Encourages STEL, GORO, SKYT, VTYX Shareholders to Contact the Firm to Discuss Their Rights - InsideNoVa.com
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--SKYT, GORO, STEL, and VTYX - Benzinga
Does Ventyx Biosciences Inc offer margin of safetyWeekly Profit Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Lilly-Ventyx US premerger waiting period set to expire Feb. 23 - MLex
Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger - TipRanks
Aug Movers: Is QMCO stock a hidden gemEarnings Performance Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Chipmakers Recap: Does Ventyx Biosciences Inc meet Warren Buffetts criteriaJuly 2025 Technicals & Growth Focused Entry Reports - baoquankhu1.vn
Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Drops By 37.7% - MarketBeat
Will Ventyx Biosciences Inc. benefit from rate cutsEarnings Beat & Daily Price Action Insights - mfd.ru
Halper Sadeh LLC Encourages NATH, VTYX, SKYT Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ventyx Biosciences Inc Stock (VTYX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohan Raju | CEO AND PRESIDENT |
Dec 18 '25 |
Sale |
7.72 |
47,345 |
365,461 |
2,372,863 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 17 '25 |
Option Exercise |
0.00 |
34,930 |
0 |
502,156 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Dec 18 '25 |
Sale |
7.72 |
12,675 |
97,840 |
489,481 |
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):